Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).

Lou Y, Lopez F, Jiang Y, Han X, Brotherton C, Billedeau R, Gabriel S, Gleason S, Goldstein DM, Hilgenkamp R, Kocer B, Orzechowski L, Tan J, Wovkulich P, Wen B, Fry D, Di Lello P, Chen L, Zhang FJ, Fretland J, Nangia A, Yang T, Owens TD.

Bioorg Med Chem Lett. 2017 Feb 1;27(3):632-635. doi: 10.1016/j.bmcl.2016.11.092. Epub 2016 Dec 2.

PMID:
28025004
2.

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.

Vu B, Wovkulich P, Pizzolato G, Lovey A, Ding Q, Jiang N, Liu JJ, Zhao C, Glenn K, Wen Y, Tovar C, Packman K, Vassilev L, Graves B.

ACS Med Chem Lett. 2013 Apr 2;4(5):466-9. doi: 10.1021/ml4000657. eCollection 2013 May 9.

3.

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

Anderson K, Chen Y, Chen Z, Dominique R, Glenn K, He Y, Janson C, Luk KC, Lukacs C, Polonskaia A, Qiao Q, Railkar A, Rossman P, Sun H, Xiang Q, Vilenchik M, Wovkulich P, Zhang X.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5. doi: 10.1016/j.bmcl.2013.10.055. Epub 2013 Nov 1.

PMID:
24239188
4.

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.

Liu JJ, Higgins B, Ju G, Kolinsky K, Luk KC, Packman K, Pizzolato G, Ren Y, Thakkar K, Tovar C, Zhang Z, Wovkulich PM.

ACS Med Chem Lett. 2013 Jan 15;4(2):259-63. doi: 10.1021/ml300351e. eCollection 2013 Feb 14.

5.

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.

Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, Tardell C, Garrido R, Lee E, Kolinsky K, To KH, Linn M, Podlaski F, Wovkulich P, Vu B, Vassilev LT.

Cancer Res. 2013 Apr 15;73(8):2587-97. doi: 10.1158/0008-5472.CAN-12-2807. Epub 2013 Feb 11.

6.

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Chen S, Bartkovitz D, Cai J, Chen Y, Chen Z, Chu XJ, Le K, Le NT, Luk KC, Mischke S, Naderi-Oboodi G, Boylan JF, Nevins T, Qing W, Chen Y, Wovkulich PM.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1247-50. doi: 10.1016/j.bmcl.2011.11.052. Epub 2011 Dec 1.

PMID:
22172702
7.

Preclinical evaluation of the novel multi-targeted agent R1530.

Kolinsky K, Tovar C, Zhang YE, Railkar A, Yang H, Carvajal D, Nevins T, Geng W, Linn M, Packman K, Liu JJ, Zhang Z, Wovkulich P, Ju G, Higgins B.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1585-94. doi: 10.1007/s00280-011-1608-x. Epub 2011 May 8.

PMID:
21553286
8.

Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.

Liu JJ, Daniewski I, Ding Q, Higgins B, Ju G, Kolinsky K, Konzelmann F, Lukacs C, Pizzolato G, Rossman P, Swain A, Thakkar K, Wei CC, Miklowski D, Yang H, Yin X, Wovkulich PM.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):5984-7. doi: 10.1016/j.bmcl.2010.08.079. Epub 2010 Aug 21.

PMID:
20832307
9.

(23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis.

Horst RL, Wovkulich PM, Baggiolini EG, Uskoković MR, Engstrom GW, Napoli JL.

Biochemistry. 1984 Aug 14;23(17):3973-9.

PMID:
6548386

Supplemental Content

Loading ...
Support Center